Us Congress 2023-2024 Regular Session

Us Congress House Bill HB2296

Introduced
3/29/23  
Refer
3/29/23  

Caption

To provide for a limitation on availability of funds for Related Agency and Food and Drug Administration, Buildings and Facilities for fiscal year 2024.

Impact

If enacted, HB2296 will directly affect the budget management of the FDA and related agencies, imposing a strict ceiling on the financial resources available for operational purposes in 2024. This limitation could lead to adjustments in how these agencies plan and execute projects related to public health, as well as the maintenance and improvement of their facilities. With fiscal constraints in place, organizations may have to prioritize essential operations and potentially delay or scale back other initiatives.

Summary

House Bill 2296 seeks to place a limitation on the availability of funds for the Related Agency and the Food and Drug Administration (FDA), specifically concerning Buildings and Facilities for the fiscal year 2024. This bill authorizes an appropriation cap of $11,788,000 for these agencies, intending to streamline financial allocations and potentially reduce spending within the federal budget framework. The emphasis on limiting funding stems from a broader political agenda aimed at restructuring fiscal priorities and reducing government expenditure in certain sectors.

Conclusion

As discussions surrounding HB2296 continue, stakeholders will likely weigh the fiscal responsibility of limiting spending against the necessity of maintaining robust health oversight. The bill reflects ongoing debates about federal spending priorities and the extent to which financial limitations might compromise essential services provided by agencies like the FDA.

Contention

The bill could generate points of contention regarding the adequacy of funding for critical health infrastructure and the operational capabilities of the FDA. Advocates for public health and safety may argue that reducing funding hampers the FDA's ability to ensure food and drug safety, manage healthcare facilities, and implement crucial regulatory functions. Additionally, there may be concerns about the implications of tight budgets leading to staffing shortages or a slowdown in response times for public health challenges.

Companion Bills

No companion bills found.

Previously Filed As

US HB2295

To provide for a limitation on availability of funds for Related Agency and Food and Drug Administration, Department of Health and Human Services, Food and Drug Administration, for fiscal year 2024.

US HB2297

To provide for a limitation on availability of funds for Related Agency and Food and Drug Administration, FDA Innovation Account, Cures Act for fiscal year 2024.

US HB2193

To provide for a limitation on availability of funds for Environmental Protection Agency,, Buildings and Facilities for fiscal year 2024.

US HB2044

To provide for a limitation on availability of funds for Related Agencies, National Mediation Board for fiscal year 2024.

US HB2106

To provide for a limitation on availability of funds for Independent Agencies, Administrative Conference of the US for fiscal year 2024.

US HB2256

To provide for a limitation on availability of funds for US Department of Agriculture, Animal and Plant Health Inspection Service Buildings and Facilities for fiscal year 2024.

US HB2288

To provide for a limitation on availability of funds for US Department of Agriculture, Food and Nutrition Service, Nutrition Programs Administration for fiscal year 2024.

US HB2041

To provide for a limitation on availability of funds for Related Agencies, The Institute of Museum and Library Services for fiscal year 2024.

US HB2043

To provide for a limitation on availability of funds for Related Agencies, National Labor Relations Board, Salaries and Expenses for fiscal year 2024.

US HB2042

To provide for a limitation on availability of funds for Related Agencies, National Council on Disability for fiscal year 2024.

Similar Bills

No similar bills found.